Amalgamated Bank Sells 194 Shares of Insulet Co. (NASDAQ:PODD)

Amalgamated Bank lowered its stake in Insulet Co. (NASDAQ:PODD) by 1.3% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 14,548 shares of the medical instruments supplier’s stock after selling 194 shares during the quarter. Amalgamated Bank’s holdings in Insulet were worth $3,798,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Blue Trust Inc. increased its holdings in shares of Insulet by 84.1% during the third quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock valued at $30,000 after acquiring an additional 58 shares in the last quarter. International Assets Investment Management LLC grew its position in Insulet by 23,175.0% during the 3rd quarter. International Assets Investment Management LLC now owns 37,240 shares of the medical instruments supplier’s stock valued at $8,668,000 after purchasing an additional 37,080 shares during the last quarter. Arkadios Wealth Advisors increased its stake in Insulet by 28.9% during the 3rd quarter. Arkadios Wealth Advisors now owns 1,286 shares of the medical instruments supplier’s stock valued at $299,000 after purchasing an additional 288 shares in the last quarter. DekaBank Deutsche Girozentrale raised its holdings in Insulet by 20.3% in the third quarter. DekaBank Deutsche Girozentrale now owns 11,720 shares of the medical instruments supplier’s stock worth $2,684,000 after buying an additional 1,980 shares during the last quarter. Finally, State of Alaska Department of Revenue lifted its stake in shares of Insulet by 7.3% in the third quarter. State of Alaska Department of Revenue now owns 8,122 shares of the medical instruments supplier’s stock worth $1,890,000 after buying an additional 550 shares in the last quarter.

Insider Activity at Insulet

In other Insulet news, CAO Lauren Budden sold 915 shares of Insulet stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total transaction of $252,192.30. Following the transaction, the chief accounting officer now owns 5,733 shares of the company’s stock, valued at $1,580,129.46. The trade was a 13.76 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Eric Benjamin sold 12,394 shares of the stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the completion of the sale, the executive vice president now directly owns 11,383 shares of the company’s stock, valued at approximately $3,187,240. This trade represents a 52.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.47% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on PODD shares. Stifel Nicolaus raised their price target on shares of Insulet from $245.00 to $293.00 and gave the company a “hold” rating in a research report on Friday, February 21st. Morgan Stanley lifted their target price on Insulet from $234.00 to $317.00 and gave the stock an “overweight” rating in a report on Monday, November 11th. Barclays boosted their price target on Insulet from $220.00 to $234.00 and gave the stock an “equal weight” rating in a research note on Monday, November 11th. BTIG Research increased their price objective on Insulet from $260.00 to $270.00 and gave the company a “buy” rating in a research report on Friday, November 8th. Finally, TD Cowen boosted their target price on Insulet from $264.00 to $324.00 and gave the stock a “buy” rating in a research report on Friday, January 3rd. Three research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $289.06.

Insulet Trading Up 1.9 %

Shares of Insulet stock opened at $272.27 on Friday. Insulet Co. has a 1-year low of $160.19 and a 1-year high of $289.46. The company’s fifty day simple moving average is $274.01 and its 200-day simple moving average is $249.91. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The stock has a market capitalization of $19.10 billion, a PE ratio of 47.02, a P/E/G ratio of 3.62 and a beta of 1.23.

Insulet (NASDAQ:PODD) last released its earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.00 by $0.15. The company had revenue of $597.50 million for the quarter, compared to the consensus estimate of $582.02 million. Insulet had a return on equity of 24.46% and a net margin of 20.19%. As a group, equities analysts anticipate that Insulet Co. will post 3.92 earnings per share for the current year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.